Skip to main content
Top
Published in: Medical Microbiology and Immunology 5-6/2022

Open Access 02-09-2022 | Pharyngitis | Original Investigation

Low rate of asymptomatic carriage and salivary immunoglobulin A response to Group A Streptococci in the healthy adult population in Finland

Authors: Emilia Lönnqvist, Kirsi Gröndahl-Yli-Hannuksela, Vuokko Loimaranta, Jaana Vuopio

Published in: Medical Microbiology and Immunology | Issue 5-6/2022

Login to get access

Abstract

Streptococcus pyogenes, also called group A streptococcus (GAS), is a human pathogen causing a wide range of infections ranging from mild tonsillitis to severe, life threatening conditions such as bacteraemia, necrotizing fasciitis, and streptococcal toxic shock syndrome. GAS may also colonise the oropharynx without causing any signs of disease which is known as asymptomatic carriage. This study aims to investigate IgA responses against GAS and oral streptococci from saliva samples collected from healthy Finnish adults. In addition, asymptomatic throat GAS carriage was studied. The study participants consisted of healthy adult volunteers who provided one saliva sample, a throat swab, and a background questionnaire. Total salivary IgA, and GAS specific IgA were analysed from the saliva samples using enzyme-linked immunosorbent assays (ELISA) and the results were compared to oral streptococci specific IgA levels. Asymptomatic GAS throat carriers were identified by bacterial culture, and the isolates were emm typed. Samples from a total of 182 individuals were analysed. The median salivary IgA concentration was 62.9 µg/ml (range 17.3–649.9 µg/ml), and median GAS and oral streptococcal specific IgA concentrations 2.7 and 3.3 arbitrary units (AU, range 1.4–7.4 AU and 1.6–12.0 AU), respectively. Three individuals with asymptomatic GAS throat carriage were identified.
Literature
2.
go back to reference Carapetis JR, Steer AC, Mulholland EK, Weber M (2005) The global burden of group A streptococcal diseases. Lancet Infect Dis 5:685–694CrossRefPubMed Carapetis JR, Steer AC, Mulholland EK, Weber M (2005) The global burden of group A streptococcal diseases. Lancet Infect Dis 5:685–694CrossRefPubMed
21.
go back to reference Vilhonen J, Vuopio J, Vahlberg T, Gröndahl-Yli-Hannuksela K, Rantakokko-Jalava K, Oksi J (2020) Group A streptococcal bacteremias in Southwest Finland 2007–2018: epidemiology and role of infectious diseases concultation in antibiotic treatment selection. Eur J Clin Microbiol Infect Dis 39:1339–1348CrossRefPubMedPubMedCentral Vilhonen J, Vuopio J, Vahlberg T, Gröndahl-Yli-Hannuksela K, Rantakokko-Jalava K, Oksi J (2020) Group A streptococcal bacteremias in Southwest Finland 2007–2018: epidemiology and role of infectious diseases concultation in antibiotic treatment selection. Eur J Clin Microbiol Infect Dis 39:1339–1348CrossRefPubMedPubMedCentral
26.
go back to reference Ostergaard PA (1977) IgA levels and carrier rate of pathogenic bacteria in 27 children previously tonsillectomized. Acta Pathol Microbiol Scand Sect C, Immunol 85:178–186 Ostergaard PA (1977) IgA levels and carrier rate of pathogenic bacteria in 27 children previously tonsillectomized. Acta Pathol Microbiol Scand Sect C, Immunol 85:178–186
Metadata
Title
Low rate of asymptomatic carriage and salivary immunoglobulin A response to Group A Streptococci in the healthy adult population in Finland
Authors
Emilia Lönnqvist
Kirsi Gröndahl-Yli-Hannuksela
Vuokko Loimaranta
Jaana Vuopio
Publication date
02-09-2022
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 5-6/2022
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-022-00750-9

Other articles of this Issue 5-6/2022

Medical Microbiology and Immunology 5-6/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.